Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) Shares Outstanding (Diluted Average) (2022 - 2025)

Lucid Diagnostics' Shares Outstanding (Diluted Average) history spans 4 years, with the latest figure at $92.1 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 82.89% year-over-year to $92.1 million; the TTM value through Sep 2025 reached $92.1 million, up 82.89%, while the annual FY2024 figure was $50.5 million, 20.98% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $92.1 million in Q3 2025 per LUCD's latest filing, down from $99.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $99.0 million in Q2 2025 to a low of $35.4 million in Q2 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $52.0 million, with a median of $43.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): grew 9.87% in 2024, then soared 105.32% in 2025.
  • A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $36.2 million in 2022, then grew by 15.44% to $41.8 million in 2023, then increased by 20.98% to $50.5 million in 2024, then soared by 82.38% to $92.1 million in 2025.
  • Per Business Quant, the three most recent readings for LUCD's Shares Outstanding (Diluted Average) are $92.1 million (Q3 2025), $99.0 million (Q2 2025), and $68.8 million (Q1 2025).